儿童RPE65相关视网膜病变基因治疗后的视觉结局
这项回顾性病例系列纳入14例(27眼)接受Voretigene neparvovec治疗的RPE65双等位基因致病变异儿童,中位治疗年龄6.88岁、随访3.42年。排除4眼超视力表转换后视力变化小于1行;10例完成图形视觉诱发电位者中7例临床意义改善、2例因脉络膜视网膜萎缩恶化;常见并发症为短暂炎症和局部萎缩。
要点
- 治疗后视力从logMAR 1.00改善至0.76,但排除超视力表转换后变化小于1行。
- 10例完成图形VEP者中7例临床意义改善,支持其作为幼儿客观结局指标。
- 并发症包括短暂炎症(5/14)和局部萎缩(6/14)。
核心结论
- VN治疗儿童 RPE65 相关视网膜病变可见视觉改善,但排除超视力表转换后视力改善不明确。
- 图形VEP可客观反映视网膜-膝状体-纹状体通路恢复,支持用于未来幼儿试验的结局指标。
研究设计与样本
- 中位治疗年龄6.88岁(IQR 3.27-8.83),中位随访3.42年(IQR 2.65-4.08)。
主要发现
- 视力从logMAR 1.00改善至0.76(差值-0.24)。
- 排除4眼超视力表转换后,视力变化为-0.03(logMAR 0.74至0.71,即20/100至20/100)。
- 仅3眼(14例中)完成可靠全视野刺激测试,平均20.6 dB(SD 14.8)。
- 10例完成图形VEP:7例临床意义改善,2例恶化伴脉络膜视网膜萎缩,1例不变。
- 并发症:短暂炎症5/14(35.7%),局部萎缩6/14(42.9%)。
临床怎么用
- 对幼儿 RPE65 相关视网膜病变,可结合图形VEP客观评估治疗后视觉通路恢复。
- 需关注短暂炎症和局部萎缩等并发症。
- 解读视力改善时应注意超视力表转换的影响。
局限性
- 回顾性单中心病例系列,样本量小(14例27眼)。
- 仅3眼完成可靠FST,FST数据有限。
- 部分视力数据依赖超视力表转换,排除后改善不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Voretigene neparvovec (VN) marketed as Luxturna (Novartis Europharm Ltd) is the first approved gene therapy for severe RPE65-related retinal dystrophy, showing low-luminance vision improvement in adult trials. Low-luminance tests pose challenges for children, but pattern visual evoked potentials (VEPs) need minimal cooperation and provide objective measures of visual activation of the striate cortex. In this study, VN outcomes in young children were assessed using pattern VEPs in addition to standard measures. OBJECTIVE: To evaluate vision outcomes and complications after VN treatment in children. DESIGN, SETTING, AND PARTICIPANTS: This was a retrospective case series of children receiving VN from February 2020 to December 2023. Children with biallelic pathogenic variants in RPE65 were recruited from Great Ormond Street Hospital, a single-center, UK specialist pediatric hospital. EXPOSURE: Treatment with VN, a recombinant adeno-associated virus vector-based gene therapy. MAIN OUTCOMES AND MEASURES: Pretreatment and posttreatment pattern VEPs, visual acuity (VA), full-field stimulus test (FST), optical coherence tomography (OCT) measures, and ocular complications. RESULTS: A total of 14 pediatric patients (27 eyes) were included in this analysis. Median (IQR) age at treatment of 9 female (64.3%) and 5 male (35.7%) patients was 6.88 (3.27-8.83) years, with a median (IQR) follow-up of 3.42 (2.65-4.08) years. VA improved from logMAR 1.00 to 0.76 (difference, -0.24). When 4 off-chart VA conversions were excluded, the change was less than 1 line, -0.03 (pretreatment, logMAR 0.74 [20/100] to posttreatment, 0.71 [20/100]). Only 3 eyes of 14 children (11%) completed a reliable full-field stimulus test, showing a mean (SD) 20.6 (14.8) dB. All 10 tested patients completed pattern VEPs; 7 showed clinically meaningful improvement, 2 worsened with chorioretinal atrophy, and 1 remained unchanged. Complications included transient inflammation (5 of 14 patients [35.7%]) and localized atrophy (6 of 14 patients [42.9%]). CONCLUSIONS AND RELEVANCE: This case series study reports VN-treated patients as young as 15 months, confirming visual improvements, although not necessarily VA when off-chart VA conversions were excluded, consistent with previously reported outcomes. Pattern VEPs provided an objective measure of retinogeniculostriate recovery, supporting their use as an outcome measure in future trials for young children with inherited retinal diseases.
引用
- Thompson DA, De Smit E, Tan W, et al. Vision Outcomes in Children Treated With Voretigene Neparvovec for RPE65-Associated Retinopathy. JAMA Ophthalmol. 2026. PMID: 41481309. doi:10.1001/jamaophthalmol.2025.5505
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。